Evidence Synthesis
Number 125

Screening for Breast Cancer With Digital Breast Tomosynthesis

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857
www.ahrq.gov

Contract No. HHSA-290-2012-00015-I, Task Order No. 5

Prepared by:
Center for Healthcare Policy and Research
University of California, Davis
Sacramento, CA

Kaiser Permanente Research Affiliates Evidence-based Practice Center
Kaiser Permanente Center for Health Research
Portland, OR

Investigators:
Joy Melnikow, MD, MPH
Joshua J. Fenton, MD, MPH
Diana Miglioretti, PhD
Evelyn P. Whitlock, MD, MPH
Meghan S. Weyrich, MPH

AHRQ Publication No. 14-05201-EF-2
January 2016
This report is based on research conducted by the University of California, Davis Center for Healthcare Policy and Research and the Kaiser Permanente Research Affiliates Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2012-00015-I, Task Order No. 5). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

**Suggested Citation**

Table of Contents

Chapter 1. Introduction ............................................................................................................... 1  
  Purpose........................................................................................................................................ 1  
  Background................................................................................................................................. 1

Chapter 2. Methods ...................................................................................................................... 2  
  Key Question .............................................................................................................................. 2  
  Data Sources and Searches ......................................................................................................... 2  
  Study Selection ........................................................................................................................... 2  
  Quality Assessment and Data Abstraction.................................................................................. 2

Chapter 3. Results ......................................................................................................................... 4  
  Literature Search......................................................................................................................... 4  
  Summary of Results..................................................................................................................... 4  
    Test Performance of DBT ....................................................................................................... 4  
    Proximate Health Outcomes of DBT ...................................................................................... 5

Chapter 4. Discussion ................................................................................................................... 6

References...................................................................................................................................... 7

Tables
Table 1. Screening for Breast Cancer Using Digital Breast Tomosynthesis: Study Details and 
  Test Performance Characteristics
Table 2. Screening for Breast Cancer Using Digital Breast Tomosynthesis: Study Details and 
  Proximate Health Outcomes

Appendixes
Appendix A. Detailed Methods
Appendix B. Ongoing Studies and Trials Pending Assessment
Chapter 1. Introduction

Purpose

Digital breast tomosynthesis (DBT) has rapidly been adopted by many providers of mammography screening in the United States. This report summarizes the evidence published through October 2015 regarding the diagnostic test characteristics of tomosynthesis in screening populations.

Background

DBT, also known as 3D mammography, uses a computer algorithm to reconstruct multiple low-dose digital images of the breast into thin “slices” spanning the entire breast. These images can be displayed individually or in cine mode. Tomosynthesis is typically performed as a supplement to standard two-view digital screening mammography, which more than doubles the total radiation exposure compared to a standard digital mammography screening examination.1-5 In 2013, the U.S. Food and Drug Administration (FDA) approved the use of synthetic 2D images to take place of the standard 2-D, two-view digital mammograms. While this technology eliminates the additional radiation of a digital mammogram, it is currently not known how frequently synthetic views are used.1 A General Electric tomosynthesis system was approved by the FDA in September 2014,6 and a single 3D view from this system is reported to have a similar radiation dose as a standard two-view digital mammography examination.7 However, it is not yet clear how this system will be used in practice.
Chapter 2. Methods

Key Question

Using the USPSTF’s methods\(^8\) (detailed in Appendix A), we addressed the following key question:

1. What are the test performance characteristics of DBT as a primary screening modality for breast cancer, performed either alone or simultaneously with 2D digital mammography? How do these performance characteristics differ by age and risk factors?

Data Sources and Searches

We searched MEDLINE, PubMed, Embase, and the Cochrane library from January 2000 through October 2015. To ensure the comprehensiveness of our retrieval strategy, we reviewed the reference lists of included studies and relevant systematic reviews to identify relevant articles. We also supplemented our database searches with suggestions from experts, searched the grey literature for relevant reports and reviewed their references, and searched Clinicaltrials.gov to identify relevant ongoing trials (Appendix B).

Study Selection

Two reviewers independently screened titles and abstracts for relevance. For inclusion, we required studies to: 1) be conducted in screening populations (asymptomatic women aged 40 years and older), and 2) evaluate test performance characteristics with a comprehensive reference standard applied to both negative and positive tests. For breast cancer screening, this requires further imaging and/or biopsy of positive results, and a minimum of 1 year of clinical followup for negative results to ascertain interval breast cancers not identified by screening.

Quality Assessment and Data Abstraction

Two reviewers independently assessed the full text of each study to assess whether it met our predefined inclusion criteria. Two reviewers independently assessed the methodological quality of each study using predefined criteria developed by the USPSTF\(^9\) and supplemented with the National Institute for Health and Clinical Excellence methodology checklists\(^10\) and the QAREL tool\(^11\) for assessing diagnostic reliability. Disagreements in quality were resolved by discussion. Each study was given a final quality rating of good, fair, or poor. To illustrate the state of available research addressing this key question, results from screening population studies were abstracted into a standard evidence table. A second reviewer checked the data for accuracy. Elements abstracted included population characteristics (e.g., baseline demographics, family or personal history of breast cancer), study design (e.g., inclusion/exclusion criteria, followup, screening rounds), screening environment (e.g., number of readers), and test performance
characteristics (e.g., sensitivity, specificity, positive predictive value). When available, we also abstracted proximate health outcomes (e.g., breast cancer detection rates, invasive breast cancer detection rates, recall rates, and biopsy rates).
Chapter 3. Results

Literature Search

Our literature search yielded 1,024 unique citations. From these, we identified 18 articles for full-text review based on titles and abstract, including a systematic review of the use of DBT for breast cancer screening or diagnosis performed by the Technology Evaluation Center.\textsuperscript{12} This review identified one additional study we had not previously located.\textsuperscript{13} After screening the full-text articles, we identified one study meeting inclusion criteria of reporting test performance characteristics of DBT in a screening population.

Summary of Results

The evidence available on test performance characteristics of DBT was limited to a single study conducted in Italy. This study met inclusion criteria since it reported results on a screening population and employed a comprehensive reference standard. We found no studies that described the difference in test performance characteristics of DBT by age or risk factor.

We excluded nine studies from this review.\textsuperscript{1, 12, 14-20} One small study from Sweden included both symptomatic and asymptomatic women.\textsuperscript{18} This study also applied a comprehensive reference standard, including 1 year of clinical followup. However, of 185 total women, 89 (48\%) were diagnosed with breast cancer, so the study sample was not representative of a screening population. Five studies utilized test sets of mammograms with known diagnoses, with and without DBT images, to evaluate radiologist diagnostic performance.\textsuperscript{1, 15-17, 20} All of these test sets were enriched with images of known breast cancers, ranging from 16 percent\textsuperscript{16} to 41 percent\textsuperscript{1} of the total images. Two studies recruited women with abnormal mammograms.\textsuperscript{14, 19}

To illustrate the state of available research addressing the proximate health outcomes of DBT screening, the characteristics of the additional studies identified are briefly summarized in this report.

Test Performance of DBT

The single good-quality study meeting inclusion criteria (the Screening with Tomosynthesis OR standard Mammography [STORM] trial) assembled a prospective, single cohort of 7,292 women aged 48 years or older from population-based screening programs from two towns in Northern Italy.\textsuperscript{\textsuperscript{5, 21}} Women were recruited from August 2011 to June 2012, and underwent both digital mammography and DBT. Mammograms were interpreted sequentially by eight trained radiologists. Initially the 2D mammogram was read, and then the 2D and DBT images were interpreted together by the same radiologist during the same session. The study utilized independent double reading but reports results from the initial single reader; these results, which more closely resemble U.S. practice, are reported here. Median followup was 19.7 months. The study was rated as good quality based on the screening population, application of a reference
standard to those with both positive and negative results, and adequate follow-up time. Overall, 63 women were diagnosed with 65 breast cancers over the course of the study. Sensitivity for a single reading with digital mammography was 0.54 (95% CI, 0.42 to 0.65) compared with 0.85 (95% CI, 0.74 to 0.92) for DBT. Specificity for digital mammography was 0.96 (95% CI, 0.95 to 0.98) and 0.97 (95% CI, 0.96 to 0.98) for DBT with mammography (Table 1). The overall cancer detection rates were 4.8 per 1,000 women with digital mammography and 7.4 per 1,000 women with DBT with mammography. Recall rates were 4.2% for digital mammography and 3.6% for DBT with mammography (Table 1).

**Proximate Health Outcomes of DBT**

Due to the limited literature on test performance characteristics of DBT, we also summarized studies reporting cancer detection outcomes, recall rates, and biopsy rates of DBT.

After excluding the previously discussed studies,1,15-18 eight screening cohort studies reported on recall rates and cancer detection rates for digital mammography with or without DBT, including the STORM trial described previously (Table 2).4, 5, 13, 21-27 These studies compared findings within a single cohort of women undergoing both studies4, 5, 21 or compared two screening cohorts, one undergoing digital mammography only compared to a cohort undergoing mammography and DBT.13, 22-25 In most of these studies, DBT was associated with an increase in the breast cancer detection rates compared to digital mammography alone. The proportions of invasive cancers with and without the use of DBT were somewhat higher with tomosynthesis in some studies4, 23-25 and similar to digital mammography in others.5, 13, 22 In most studies, compared to digital mammography, DBT was associated with reduced immediate recall rate and higher positive predictive value for an initial positive result.4, 13, 22-25 In two of four studies reporting biopsy rates, the biopsy rate was slightly higher with DBT compared to digital mammography alone.22-25
Chapter 4. Discussion

Only one study from Italy provided information on diagnostic test characteristics of tomosynthesis for breast cancer screening, and suggested markedly higher sensitivity for the combination of DBT with digital mammography. However, the sensitivity of digital mammography in this study (54%) was much lower than that found in a recent large population-based U.S. study (87%). Other studies did not report on a comprehensive reference standard or interval cancer rates. There is a pressing need for rigorous U.S.-based studies to define the test performance characteristics and long-term clinical outcomes of this rapidly diffusing breast imaging technology.

Several retrospective cohort studies suggested DBT with digital mammography is associated with reduced overall recall rates with similar or higher biopsy rates compared to digital mammography alone. One factor that may reduce immediate recall rates with tomosynthesis is that the technology obtains additional breast images at the time of initial screening. These additional images obtained at screening may obviate the need to recall many women for further imaging after 2D mammography screening. Depending on the screening technology, the additional images acquired during DBT screening, however, may double the breast radiation dose associated with screening. Technology approved by the FDA in 2013 for synthetic 2D mammography reduces the radiation dose to that of the tomosynthesis examination alone.1

In most cohort studies, cancer detection rates were somewhat higher with DBT as compared to digital mammography alone, and the proportion of invasive cancers detected was similar to or higher than the proportion detected with digital mammography alone. Ongoing studies registered with ClinicalTrials.gov are listed in Appendix B and descriptions of these studies suggest that results of the application of a comprehensive reference standard to a screening population may become available within a few years. Studies are needed that employ the standard approach to breast imaging interpretation in the United States (single reading), and that report on both interval cancers identified by a comprehensive reference standard and longer-term outcomes, including effects of the addition of DBT to digital mammography on the stage distribution of detected cancers, breast cancer recurrence or second (contralateral) breast cancers, and mortality rates.
References


Table 1. Screening for Breast Cancer Using Digital Breast Tomosynthesis: Study Details and Test Performance Characteristics

<table>
<thead>
<tr>
<th>Author, Year (Location)</th>
<th>Study Design and Setting</th>
<th>Study N</th>
<th>Radiologist/Population Characteristics</th>
<th>Breast Cancer Type</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Houssami, 2014**&lt;sup&gt;•&lt;/sup&gt;</td>
<td>Prospective cohort (1 arm)</td>
<td>7,292 women</td>
<td>8 radiologists</td>
<td>All breast cancer</td>
<td>DBT+ DM: 0.85 (0.74 to 0.92)</td>
<td>DBT + DM: 0.97 (0.96 to 0.98)</td>
</tr>
<tr>
<td><strong>STORM Trial</strong> (Italy)</td>
<td>Population screening program from 2 cities</td>
<td>DM+DBT images interpreted independently from DM only</td>
<td>Median age: 58 y</td>
<td>DM only: 0.54 (0.42 to 0.65)</td>
<td>DM only: 0.96 (0.95 to 0.97)</td>
<td></td>
</tr>
</tbody>
</table>

*Abbreviations: CI=confidence interval; DBT=digital breast tomosynthesis; DM=digital mammography; USPSTF=U.S. Preventive Services Task Force.*
<table>
<thead>
<tr>
<th>Author, Year (Location)</th>
<th>Study Design and Setting</th>
<th>Study N</th>
<th>Radiologist/Population Characteristics</th>
<th>Breast Cancer Prevalence</th>
<th>Cancer Detection Rate (% Invasive)</th>
<th>Recall/ Biopsy Rate</th>
<th>Positive Predictive Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lang, 2015 *&lt;sup&gt;26&lt;/sup&gt; Malmö Trial (Sweden)</td>
<td>Prospective cohort (1 arm) Organized screening programs</td>
<td>7,500 women DM+DBT images interpreted independently from DM only images</td>
<td>6 radiologists DBT only: 20/7500 women DM only: 46/7500 women</td>
<td>DBT only: 2.8 per 1,000 women (85.0%) DM only: 6.3 per 1,000 women (89.0%)</td>
<td>Recall: DBT only: 3.2% DM only: 2.6%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Destounis, 2014 *&lt;sup&gt;27&lt;/sup&gt; (New York)</td>
<td>Retrospective cohort (2 arm) Community breast clinic</td>
<td>DBT+DM: 524 women DM only: 524 women DM+DBT images interpreted independently from DM only</td>
<td>6 radiologists DBT+DM: 3/524 women Mean age: DBT+DM: 59 y DM only: 59 y</td>
<td>DBT+DM: 5.4 per 1,000 women (33.3%) DM only: 3.8 per 1,000 women (50.0%)</td>
<td>Recall: DBT+DM: 4.2% DM only: 11.4% Biopsy: DBT+DM: 1.1% DM only: 2.3%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Greenberg, 2014 *&lt;sup&gt;28&lt;/sup&gt; (Washington, DC area)</td>
<td>Retrospective cohort (2 arm) Community-based multi-site radiology practice</td>
<td>DBT+DM: 20,943 exams DM only: 38,674 exams</td>
<td>14 radiologists DBT+DM: 131/20,943 exams DM only: 190/38,674 exams</td>
<td>DBT+DM: 6.3 per 1,000 exams (73.6%) DM only: 4.9 per 1,000 exams (62.1%)</td>
<td>Recall: DBT+DM: 13.6% DM only: 16.2% Biopsy: DBT+DM: 2.6% DM only: 2.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friedewald, 2014 *&lt;sup&gt;29&lt;/sup&gt; (Multi-state)</td>
<td>Retrospective cohort (2 arm) 13 academic health centers and community breast diagnostic/screening centers</td>
<td>DBT+DM: 173,663 exams DM only: 281,187 exams</td>
<td>139 radiologists DBT+DM: 950/173,663 exams DM only: 1207/281,187 exams</td>
<td>DBT+DM: 5.5 per 1,000 exams (74.5%) DM only: 4.3 per 1,000 (67.4%)</td>
<td>Recall: DBT+DM: 8.9% DM only: 10.6% Biopsy: DBT+DM: 1.9% DM only: 1.8%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*DBT = Digital Breast Tomosynthesis
*DM = Digital Mammography

NR = Not Reported
<table>
<thead>
<tr>
<th>Author, Year (Location)</th>
<th>Study Design and Setting</th>
<th>Study N</th>
<th>Radiologist/ Population Characteristics</th>
<th>Breast Cancer Prevalence</th>
<th>Cancer Detection Rate (% Invasive)</th>
<th>Recall/ Biopsy Rate</th>
<th>Positive Predictive Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Houssami, 2014 (Italy)</td>
<td>Prospective cohort (1 arm)</td>
<td>7,292 women</td>
<td>8 radiologists</td>
<td>DBT+DM: 55/7292 women</td>
<td>DBT+DM: 7.4 per 1,000 women</td>
<td>Recall DBT+DM: 3.6%</td>
<td>DBT+DM: 21%</td>
</tr>
<tr>
<td></td>
<td>Population screening program from 2 cities</td>
<td>DM+DBT images interpreted independently from DM only</td>
<td>Median age: 58 y</td>
<td>DM only: 35/7292 women</td>
<td>DM only: 4.8 per 1,000 women</td>
<td>DM only: 4.2%</td>
<td>DM only: 11%</td>
</tr>
<tr>
<td>McCarthy, 2014 (Pennsylvania)</td>
<td>Cohort (2 arm)</td>
<td>15,571 exams</td>
<td>6 radiologists</td>
<td>DBT+DM: 85/15,571 exams</td>
<td>DBT+DM: 5.5 per 1,000 exams (71%)</td>
<td>Recall DBT+DM: 8.8%</td>
<td>DBT+DM: 6.2%</td>
</tr>
<tr>
<td></td>
<td>One academic medical center</td>
<td>DM only: 10,728 exams</td>
<td>Mean age</td>
<td>DM only: 49/10728 exams</td>
<td>DM only: 4.6 per 1,000 exams (69%)</td>
<td>DM only: 10.4%</td>
<td>DM only: 4.4%</td>
</tr>
<tr>
<td>Haas, 2013 (Connecticut)</td>
<td>Retrospective cohort (2 arm)</td>
<td>6,100 women</td>
<td>8 radiologists</td>
<td>DBT+DM: 35/6,100 women</td>
<td>DBT+DM: 5.7 per 1,000 women (69%)</td>
<td>Recall DBT+DM: 8.4%</td>
<td>DBT+DM: 6.8%</td>
</tr>
<tr>
<td></td>
<td>Multi-site (1 academic medical center, 2 outpatient radiology clinics, 1 mobile mammography van)</td>
<td>DM only: 7,058 women</td>
<td>Mean age</td>
<td>DM only: 37/7,058 women</td>
<td>DM only: 5.2 per 1,000 women (68%)</td>
<td>DM only: 12.0%</td>
<td>DM only: 4.3%</td>
</tr>
<tr>
<td>Rose, 2013 (Texas)</td>
<td>Cohort (2 arm)</td>
<td>9,499 exams</td>
<td>6 radiologists</td>
<td>DBT+DM: 51/9,499 exams</td>
<td>DBT+DM: 5.4 per 1,000 exams (80%)</td>
<td>Recall DBT+DM: 5.5%</td>
<td>DBT+DM: 10.1%</td>
</tr>
<tr>
<td></td>
<td>Multisite community-based comprehensive breast cancer center</td>
<td>DM only: 13,856 exams</td>
<td>Asymptomatic women</td>
<td>DM only: 56/13,856 exams</td>
<td>DM only: 4.0 per 1,000 exams (70%)</td>
<td>DM only: 8.7%</td>
<td>DM only: 4.1%</td>
</tr>
<tr>
<td>Skaane, 2013 (Norway)</td>
<td>Prospective cohort (1 arm)</td>
<td>12,621 exams</td>
<td>8 radiologists</td>
<td>DBT+DM: 101/12,621 exams</td>
<td>DBT+DM: 8.0 per 1,000 exams (80.2%)</td>
<td>Recall DBT+DM: 6.1%</td>
<td>DBT+DM: 13.1%</td>
</tr>
<tr>
<td></td>
<td>City-wide (Oslo) breast cancer screening program</td>
<td>DM+DBT images interpreted independently from DM only images</td>
<td>Median age: 58 y</td>
<td>DM only: 77/12,621 exams</td>
<td>DM only: 6.1 per 1,000 exams (72.7%)</td>
<td>DM only: 6.7%</td>
<td>DM only: 9.1%</td>
</tr>
</tbody>
</table>

*Possible inclusion of data from Rose (2013) and Greenberg (2014).

**Abbreviations**: BC=breast cancer; DBT=digital breast tomosynthesis; DM=digital mammography; hx=history; NR=not reported; PPV=positive predictive value.
References

References


Appendix A. Detailed Methods

Key Question Literature Search Strategy

Note: The literature search strategy for this supplemental review overlapped with our main evidence review, *Adjunctive Screening for Breast Cancer in Women with Dense Breasts*, and is therefore not limited to only DBT.

Database: Cochrane
Search Strategy:

'\textit{mammogra* AND screen* AND (breast density OR dense breast OR parenchym*) in Title, Abstract, Keywords}"

Database: Ovid MEDLINE(R)
Search Strategy:

1. "\textit{breast densit*".ti,ab.
2. parenchym*.ti,ab.
3. mammo* pattern.ti,ab.
4. mammo* patterns.ti,ab.
5. radiological pattern*.ti,ab.
6. wolfe*.ti,ab.
7. tabar*.ti,ab.
8. mammo* feature*.ti,ab.
9. breast pattern*.ti,ab.
10. mammo* densit*.ti,ab.
11. tissue densit*.ti,ab.
12. or/1-11
13. (\textit{negative test result* or false negative}).mp. or exp False Negative Reactions/
14. "\textit{sensitivity and specificity}"/ or "\textit{limit of detection}"/ or roc curve/ or signal-to-noise ratio/
15. "\textit{sensitivity and specificity}"/ or "\textit{limit of detection}"/ or roc curve/ or signal-to-noise ratio/
16. or/13-15
17. ((\textit{negative adj4 mammogra*}) or \textit{negative screen}).mp.
18. 16 or 17
19. (\textit{supplementa* adj3 screen*}).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
20. (\textit{breast or mammogra*}).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
21. 12 and 16 and 18
22. 20 and 21
23. 12 and 19
24. (((\textit{supplementa* adj5 ultraso*}) or \textit{supplementa*}) adj5 imag*).mp.
25. 12 and 24
26. 20 and 25
27. 22 or 26
Appendix A. Detailed Methods

28. 23 or 27
29. limit 28 to ((abstracts or english language) and yr="2000 -Current")

Database: Ovid MEDLINE(R)
Search Strategy:
---------------------------------------------------------------------------
1. exp "Sensitivity and Specificity"/
2. sensitivity.tw.
3. specificity.tw.
4. ((pre-test or pretest) adj probability).tw.
5. post-test probability.tw.
6. post-test probability.tw.
7. likelihood ratio$.tw.
8. or/1-7
9. Breast Neoplasms/
10. (breast adj (neoplasm or neoplasms or tumour or tumor or tumors or tumours or cancer or carcinoma or carcinomas or oncologic or oncology)).mp.
11. 9 or 10
12. exp Mammography/
14. 12 or 13
15. 8 and 14
16. "breast densit*".ti,ab.
17. parenchym*.ti,ab.
18. mammo* pattern.ti,ab.
19. mammo* patterns.ti,ab.
20. radiological pattern*.ti,ab.
21. wolfe*.ti,ab.
22. tabar*.ti,ab.
23. (birad* or bi-rad*).ti,ab.
24. mammo* feature*.ti,ab.
25. breast pattern*.ti,ab.
26. mammo* densit*.ti,ab.
27. tissue densit*.ti,ab.
28. "breast imaging reporting and data system".ti,ab.
29. or/16-28
30. 8 and 11 and 14 and 29
31. limit 30 to english language
1. 65. Image Processing, Computer-Assisted/ or Radiographic Image Interpretation, Computer-Assisted/ or Tomography, X-Ray Computed/ or Radiographic Image Enhancement/ or Tomography, X-Ray/ or tomosynthesis.mp. or Imaging, Three-Dimensional/
2. 66. 64 and 65
3. 67. Ultrasonography, Mammary/ or automated ultrasound.mp.
4. 68. whole breast ultrasound.mp.
5. 69. hand help ultrasound.mp.
6. 70. magnetic resonance imaging.mp. or Magnetic Resonance Imaging/
Appendix A. Detailed Methods

7. 71. mri.mp.
8. 72. Technetium Te 99m Sestamibi/ or scintimammography.mp.
9. 73. or/67-72
10. 74. 31 and 73
11. 75. limit 74 to (english language and yr="2000 -Current")
12. 79. or/76-78
13. 80. 62 and 79
14. 81. limit 80 to (english language and yr="2000 -Current")
15. 82. 81 not 75
16. 83. 65 or 73
17. 84. 82 and 83

Database: Embase
Search Strategy:
---------------------------------------------------------------------------
1. 'mammography'/exp OR 'mammography' OR 'mammography system'/exp OR
   'mammography system' OR mammograph*:ab,ti AND [2000-2014]/py
2. 'dosimetry'/exp OR 'dosimetry' OR 'radiation protection'/exp OR 'radiation protection' OR
   'radiation measurement'/exp OR 'radiation measurement' AND [2000-2014]/py
4. 'radiation exposure'/exp OR 'radiation exposure' OR 'radiation induced neoplasm'/exp OR
   'radiation induced neoplasm' OR 'radiation injury'/exp OR 'radiation injury' AND [2000-
   2014]/py
5. 'morbidity'/exp OR 'morbidity' OR 'mortality'/exp OR 'mortality' OR 'adverse effect':ab,ti
   OR 'adverse effects':ab,ti OR harm:ab,ti OR harms:ab,ti OR contraindic*:ab,ti AND [2000-
   2014]/py
6. #2 OR #4
7. #1 AND #5 AND #6
8.1 'breast tumor'/exp/dm_pc,dm_di
8.2 (breast NEXT/5 (neoplasm* OR tumour* OR tumor* OR cancer* OR carcinom* OR
   oncolog*)):ab,ti
8.3 #8.1 OR #8.2
8.4 'mass screening'/exp OR 'mass radiography'/exp
8.5 'neoplasm'/exp/dm_pc,dm_di
8.6 'mammography'/exp OR 'mammography system'/exp OR mammograph*:ab,ti
8.7 screen*:ab,ti
8.8 #8.4 OR #8.5 OR #8.6 OR #8.7
8.9 #8.3 AND #8.8
8.10 'sensitivity and specificity'/exp OR sensitivity:ab,ti OR specificity:ab,ti
8.11 ('pre test' OR pretest) NEAR/5 probability):ab,ti
8.12 ('pre test' OR pretest) NEAR/5 probability):ab,ti
8.13 'likelihood ratio':ab,ti OR 'likelihood ratios':ab,ti
8.14 #8.10 OR #8.11 OR #8.12 OR #8.13
8.15 #8.9 AND #8.14
8.16 'breast density':ab,ti OR 'dense breasts':ab,ti OR 'dense breast':ab,ti OR parenchym*:ab,ti
   OR 'mammographic feature':ab,ti OR 'mammographic features':ab,ti OR (mammography

Screening for Breast Cancer With DBT 16 UC Davis/Kaiser Permanente EPC
Appendix A. Detailed Methods

NEAR/2 feature*:ab,ti OR 'breast pattern':ab,ti OR 'breast patterns':ab,ti OR (breast NEAR/3 pattern):ab,ti OR 'mammographic density':ab,ti OR (mammography NEAR/3 density):ab,ti OR 'mammographic pattern':ab,ti OR 'mammographic patterns':ab,ti OR (mammography NEAR/2 patterns):ab,ti OR 'radiological pattern':ab,ti OR 'radiological patterns':ab,ti OR wolfe*:ab,ti OR tabar*:ab,ti OR birad*:ab,ti OR 'bi rad':ab,ti OR 'breast imaging reporting and data system':ab,ti OR 'tissue density':ab,ti OR (tissue NEAR/3 density):ab,ti
8.17 #8.15 AND #8.16
8.18 #8.17 AND [english]/lim AND [2000-2014]/py
## Appendix A Table 1. Inclusion and Exclusion Criteria

<table>
<thead>
<tr>
<th>Category</th>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Populations</strong></td>
<td>Women primarily aged 40 years and older receiving tomosynthesis screening</td>
<td>Women with:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pre-existing breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinically significant BRCA 1/2 mutations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Li-Fraumeni syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cowden syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hereditary diffuse gastric syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Other familial breast cancer syndromes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• High-risk breast lesions (DCIS, LCIS, ADH, ALH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Previous doses of chest radiation (&gt;20Gy) before age 30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Undergoing diagnostic or surveillance mammography</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Conducted in primary care or other setting with primary care-comparable population</td>
<td>Settings not generalizable to primary care</td>
</tr>
<tr>
<td><strong>Intervention or Exposure</strong></td>
<td>Digital breast tomosynthesis</td>
<td>Digital or full-film mammography alone; other new technologies, such as MRI or ultrasound; use for diagnostic or surveillance purposes; use in a diagnostic or surveillance setting only</td>
</tr>
<tr>
<td><strong>Comparisons or Nonexposure</strong></td>
<td>Digital or film mammography</td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Test performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios for invasive breast cancers, breast lesions [DCIS], total breast cancers, breast cancers by stage); biopsy rates, recall rates</td>
<td></td>
</tr>
<tr>
<td><strong>Study Designs</strong></td>
<td>Diagnostic accuracy studies with reference standard and more than one radiologist/reader, RCTs, cohort studies with more than one radiologist/reader, and meta-analyses</td>
<td></td>
</tr>
<tr>
<td><strong>Language</strong></td>
<td>English only</td>
<td>Non-English languages</td>
</tr>
<tr>
<td><strong>Publication Date</strong></td>
<td>Studies published from January 2000 to present</td>
<td>Studies published before January 2000</td>
</tr>
<tr>
<td><strong>Study Quality</strong></td>
<td>Fair- and good-quality studies</td>
<td>Poor-quality studies</td>
</tr>
</tbody>
</table>
### Appendix B. Ongoing Studies and Trials Pending Assessment

<table>
<thead>
<tr>
<th>Investigator (Location) Study Title/Name</th>
<th>Number of Participants/Estimated Enrollment</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>2014 Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sophia Zackrisson (Sweden) Malmö Breast Tomosynthesis Screening Trial</td>
<td>15,000</td>
<td>Screening with tomosynthesis compared to digital mammography</td>
<td>Cancer detection; sensitivity; specificity</td>
<td>Study Period: March 2010 – March 2016 Recruiting</td>
</tr>
<tr>
<td>Emily Conant (United States) Comparison of Full-Field Digital Mammography With Digital Breast Tomosynthesis Image Acquisition in Relation to Screening Call-Back Rate</td>
<td>550</td>
<td>Screening with digital mammography compared to a combination of 2D and 3D tomosynthesis</td>
<td>Recall rates; sensitivity; specificity; lesion characterization; radiation dose</td>
<td>Study Period: December 2012 – June 2012 Status unknown</td>
</tr>
<tr>
<td>Jules Sumkin (United States) Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment</td>
<td>1,080</td>
<td>Screening with digital mammography and tomosynthesis (images interpreted independently)</td>
<td>Recall rates; specificity</td>
<td>Study Period: May 2010 – May 2014 Recruiting</td>
</tr>
<tr>
<td>Per Skaane (Norway) Tomosynthesis in the Oslo Breast Cancer Screening Program (DBT)</td>
<td>25,000</td>
<td>Screening with digital mammography and tomosynthesis</td>
<td>Screening performance indicators; interval cancer rates</td>
<td>Study Period: November 2010 – September 2015 Ongoing, but not recruiting</td>
</tr>
<tr>
<td>Thomas Moritz (Austria) Digital Breast Tomosynthesis vs. Digital Mammography: A National Multicenter Trial</td>
<td>600</td>
<td>Screening with digital mammography and tomosynthesis</td>
<td>Specificity; sensitivity</td>
<td>Study Period: January 2012 – December 2012 Status unknown</td>
</tr>
</tbody>
</table>